Page 1 of 2
12

Thompson CM, Bichteler A, Rager JE, Suh M, Proctor DM, Haws LC, Harris MA. 2016. Comparison of in vivo genotoxic and carcinogenic potency to augment mode of action analysis: Case study with hexavalent chromium. Mut Res/Genet Toxicol Environ Mutagen 800-801(April):28-34; doi: 10.1016/j.mrgentox.2016.01.008.

View Abstract

Lowe KA, Danese MD, Gleeson ML, Langeberg WJ, Kelsh MA. 2016. Racial and ethnic variability in the prevalence and incidence of comorbidities associated with gastric cancer in the United States. J Gastrointest Cancer 47(2):168–181; doi: 10.1007/s12029-016-9809-5.

View Abstract

Hummel HD, Topp MS, Chang ET, Chia VM, Kelsh MA, Doemland ML, et al. 2016. Adverse events in adults with relapsed or refractory acute lymphoblastic leukemia (ALL): A literature review of recent clinical trials. J Leuk 4(1):208; doi: 10.4172/2329-6917.1000208.

View Abstract

Erichsen R, Kelsh MA, Oliner KS, Nielsen KB, Frøslev T, Lænkholm AV, et al. 2016. Prognostic impact of tumor MET expression among patients with stage IV gastric cancer: A Danish cohort study. Annals of Epidemiol 26(7):500–503.

View Abstract

Garabrant DH, Alexander DD, Miller PE, Fryzek JP, Boffetta P, Teta MJ, … Kelsh MA, et al. 2016. Mesothelioma among motor vehicle mechanics: An updated review and meta-analysis. Ann Occup Hyg 60(1):8–26.

View Abstract

Gökbuget N, Dombret H, Ribera JM, Fielding AK, Advani A, Bassan R, … Kelsh M, et al. 2016. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica 101(12):1524–1533; doi: 10.3324/haematol.2016.144311. PMID: 27587380.

View Abstract

Gökbuget N, Kelsh M, Chia V, Advani A, Bassan R, Dombret H, et al. 2016. Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. Blood Cancer J 6(9):e473.

View Abstract

Kelsh MA. Evaluating biosimilars in observational data: Some methodological considerations. Presented at International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Dublin, Ireland, August 25–28, 2016.

Thompson CM, Suh M, Mittal L, Wikoff D, Welsh B, Proctor DM. 2016. Development of linear and threshold no significant risk levels for inhalation exposure to titanium dioxide using systematic review and mode of action considerations. Regul Toxicol Pharmacol 80(Oct):60-70; doi: 10.1016/j.yrtph.2016.05.031.

View Abstract

Jensen I, Zacherle E, Blanchette C, Zhang J, Yin W. 2016. Evaluating cost benefits of combination therapies for advanced melanoma. Drugs Context 5:212297; doi: 10.7573/dic.212297.

View Abstract
Page 1 of 2
12